TCRX:NASDAQTScan Therapeutics, Inc. Analysis

TScan Therapeutics (TCRX) trades at $1.24, comfortably above the 20‑day SMA ($1.17) but still below the 200‑day SMA ($1.39), indicating a short‑term bounce within a longer‑term downtrend. The RSI at 56 suggests neutral momentum, while the MACD shows a bearish crossover (line 0.042 vs signal 0.044) and a negative histogram, warning of limited upside in the near term. Volatility is extreme at 88% over 30 days and the beta of 2.28 points to amplified moves relative to the market, compounded by decreasing volume and a support level near $1.00. Despite a negative PE and operating losses, the stock’s price‑to‑book (0.57) and price‑to‑sales (7.19) ratios are low, and the consensus target of $6 implies a potential upside of nearly 386%, reflecting strong analyst optimism. Recent material news highlights the company’s participation in the Needham Virtual Healthcare Conference and the American Society of Gene and Cell Therapy meeting, offering platforms to showcase its TCR‑T pipeline and potentially attract partnership or financing.